Stock Ratings / Health Care / IART / options

SIBN (48) BBNX (36) SGP (41) IRMD (68) ⌘ Pro Terminal →

Integra LifeSciences Holdings Corporation (IART) Options Positioning, Max Pain & Unusual Sweeps

$12.83 +4.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.92

Integra LifeSciences Holdings Corporation (IART) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $998.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $12.92 (+0.68%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IART)Realized 20D OHLCV Swing Band: ±11.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY IART SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (34% of score)

20D Institutional Volume Accumulation (±11.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (28% of score)

FRED Regime × Technicals: 35% of 52W Range • RSI-14 at 42.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$13.44-1.7% Next Q

Q2 (-2Q)

Grade E$13.21-9.8% Next Q

Q3 (-1Q)

Grade E$11.91+7.7% Next Q

Current

Grade E$12.83-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IART Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IART currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.84) and Max Pain ($13.47) forces dealer call-delta covering toward $21.51.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IART• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IART Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±11.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (IART)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for IART.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IART)

✓Walkthrough of IART's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IART // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.73%▼ DESCENDING CHANNEL

2026-10-30O $12.75H $12.86L $12.33C $12.83VOL 1.04M

RES: $15.42SUP: $11.05SMA50: $14.84SMA200: $14.07

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IART Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IART Butterfly Map → + Track IART →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +1.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IART today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IART. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IART today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IART)

Health Care Rank #886 of 1016 ⚔️ SIBN vs IART Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IART vs. SIBN, BBNX, SGP, IRMD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Integra LifeSciences Holdings Corporation (IART) ranks #886 by composite RQD confidence (32/100, grade E) and #361 by equity capitalization ($998.2M). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with IART at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IART ACTIVE Integra LifeSciences Holdings Corporation	E	32/100	—	50.9%	-35.0%	+4.82%	$998.2M	Benchmark Subject
SIBN SI-BONE Inc.	D	48/100	—	79.6%	-10.3%	+2.66%	$1.00B	/sibn-vs-iart →
BBNX Beta Bionics Inc.	D-	36/100	—	55.4%	-22.1%	-1.51%	$955.8M	/bbnx-vs-iart →
SGP SpyGlass Pharma Inc.	D-	41/100	—	—	-35.0%	-1.06%	$1.09B	/sgp-vs-iart →
IRMD iRadimed Corporation	C+	68/100	48.8x	76.7%	37.7%	+2.16%	$1.10B	/irmd-vs-iart →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000917520

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Integra LifeSciences Holdings Corporation (IART) reported GAAP revenue of $1.64B (+1.5% vs. FY2024 revenue of $1.61B , and +6.1% cumulative change since FY2023) , GAAP net income of -$516.8M, operating cash flow of $50.4M, and free cash flow of -$31.1M (-224.4% YoY). On the balance sheet, IART closed FY2025 with $3.60B in total assets against $0 in total debt (Altman Z-Score: 0.64, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.64B	-$516.8M	$50.4M	-$31.1M	$3.60B	—
FY2024 (FY)	2024-12-31	$1.61B	-$6.9M	$129.4M	$25.0M	$4.04B	—
FY2023 (FY)	2023-12-31	$1.54B	$67.7M	$140.0M	$140.0M	—	—

3. IART Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IART stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Integra LifeSciences Holdings Corporation (NASDAQ: IART) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $12.83 (+4.82% 1D, market cap $998.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IART ranks #886 in composite RQD confidence.

How does IART compare to SIBN and BBNX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), IART carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 50.9%, and ROIC of -35.0%. By comparison, SIBN (SI-BONE Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -10.3%, cap $1.00B) and BBNX (Beta Bionics Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -22.1%, cap $955.8M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IART?

Per IART's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000917520), Integra LifeSciences Holdings Corporation generated $1.64B in revenue (+1.5% YoY), -$516.8M in net income, and -$31.1M in free cash flow against $3.60B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IART trading relative to its 50-day, 200-day, and 52-week technical levels?

IART last traded at $12.83 (+4.82% on volume of 1,188,133 shares), positioning the stock -13.54% below its 50-day simple moving average ($14.84) and -8.81% below its 200-day simple moving average ($14.07). Across its 52-week range of $8.70 to $20.49, IART sits at the 35.0% percentile with a 14-day RSI of 42.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.5% ($11.35 to $14.31).

IART Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is IART's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for IART.

Direct Sub-Reports: IART RQD Cockpit IART 12M Forecast IART Earnings & Move IART Dividends & DRIP IART Insiders & 13F IART Whale Options IART Profit Sankey IART News & Why